| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Development Officer
1 company
Joanne Curley last filed a Form 4 in September 2025, as Chief Development Officer at VERA. Joanne Curley's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
Our model assigns Joanne Curley a middling insider score of 69/100, based on 21 past trades. Over a 12-month horizon, 71.4% of those trades were profitable, with an average 12-month return of +9.4%.
At the last filing, the largest reported position was 26,962 shares of VERA. The VERA filings lean toward selling, a net 102,669 shares.
Joanne Curley has 26 Form 4 filings on record from April 2021 to September 2025, across 2 companies: Director at Vistagen Therapeutics (VTGN), 2021–2025; Chief Development Officer at Vera Therapeutics (VERA), 2021–2023.
The 95 reported transactions were 48 open-market sales, 38 option exercises, 8 option or other derivative awards and 1 stock award.
Counted by filing, the open-market trades come to no purchases and 18 sales worth about $1.8M.
The largest open-market sale was 19,711 shares of VERA at an average $18.26 on December 13, 2022, about $360K. Twelve months later VERA was down 26%.
Shares as reported in the last Form 4 for each company; the most recent is from September 2025. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Aug 21, 2023 | VERA Vera Therapeutics, Inc. | Chief Development Officer | Sell10b5-1 | 1,490 | $16.66 | $24,817.14 | -5.2% | -25.0% | +123.3% | |
| Dec 16, 2022 | VERA Vera Therapeutics, Inc. | Chief Development Officer | Sale+OE | 2,212 | $19.49 | $43,115.93 | -7.6% | -64.6% | -22.0% | |
| Dec 13, 2022 | VERA Vera Therapeutics, Inc. | Chief Development Officer | Sale+OE | 19,711 | $18.26 | $359,972.96 | -42.4% | -62.3% | -25.7% | |
| Dec 7, 2022 | VERA Vera Therapeutics, Inc. | Chief Development Officer | Sell | 494 | $16.47 | $8,136.18 | -1.8% | -49.2% | -13.2% | |
| Nov 17, 2022 | VERA Vera Therapeutics, Inc. | Chief Development Officer | Sale+OE | 3,289 | $15.85 | $52,127.93 | -10.7% | -50.8% | -14.4% | |
| Nov 9, 2022 | VERA Vera Therapeutics, Inc. | Chief Development Officer | Sell | 494 | $16.54 | $8,170.76 | -1.8% | -55.0% | -27.2% | |
| Oct 18, 2022 | VERA Vera Therapeutics, Inc. | Chief Development Officer | Sale+OE | 8,590 | $19.41 | $166,734.95 | -23.6% | -60.0% | -46.4% | |
| Oct 5, 2022 | VERA Vera Therapeutics, Inc. | Chief Development Officer | Sell | 988 | $21.64 | $21,380.32 | -3.4% | -12.5% | -35.6% | |
| Sep 21, 2022 | VERA Vera Therapeutics, Inc. | Chief Development Officer | Sale+OE | 16,840 | $20.72 | $348,943.98 | -36.9% | -16.0% | -33.2% | |
| Sep 7, 2022 | VERA Vera Therapeutics, Inc. | Chief Development Officer | Sell | 988 | $18.63 | $18,406.44 | -3.3% | -17.6% | -8.0% |